About the book
Cardiac markers are the integral to the diagnosis and management of patients with cardiovascular disease (CVD). Classical enzyme biomarkers have been replaced by cardiac troponin (cTn) T (cTnT) and I (cTnI) measurements. Due to their high specificity cTn determinations are considered the gold standard in patients with suspected acute coronary syndrome (ACS). Early contemporary cTn assays were unable to detect circulating protein in healthy individuals. They also demonstrated a late diagnostic window following onset of chest pain, reflecting prognostic risk to the patient. The 99th percentile value of a healthy population is considered the optimal cut point to define an abnormal troponin concentration. With the advent of high sensitivity assays, assay design and analytical performance has an impact not only on the 99th percentile concentration but also the clinical value for diagnosis and prognosis in a range of disease states outside the remit of ACS. This edited volume will discuss how evolving cTn assay design has impacted the analytical performance and clinical utility of cTn in the established acute cardiac setting but will discuss novel uses beyond the ACS continuum.